Ginkgo Bioworks Holdings (DNA) Total Liabilities (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Total Liabilities of $589.9 million for Q1 2026, down 3.47% on a QoQ basis from $611.1 million in Q4 2025, and down 8.69% year-over-year from $646.0 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Total Liabilities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $589.9 million for Q1 2026.
- Quarterly Total Liabilities fell 8.69% year-over-year to $589.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $589.9 million (down 8.69% YoY) and the FY2025 annual result came in at $611.1 million, down 7.6% from the prior year.
- Total Liabilities was $589.9 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $611.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $809.6 million in Q1 2023 and bottomed at $427.2 million in Q2 2022.
- A 5-year average of $639.4 million and a median of $629.4 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 195.51% — and 2023, when it declined 29.25%.
- Ginkgo Bioworks Holdings' Total Liabilities stood at $803.0 million in 2022, then retreated by 29.25% to $568.2 million in 2023, then grew by 16.4% to $661.4 million in 2024, then slipped by 7.6% to $611.1 million in 2025, then decreased by 3.47% to $589.9 million in 2026.
- Business Quant data shows DNA's Total Liabilities at $589.9 million in Q1 2026, $611.1 million in Q4 2025, and $629.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 589.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589.92 Mn |
| Dec 31, 2025 | 611.11 Mn |
| Sep 30, 2025 | 629.38 Mn |
| Jun 30, 2025 | 618.06 Mn |
| Mar 31, 2025 | 646.04 Mn |
| Dec 31, 2024 | 661.39 Mn |
| Sep 30, 2024 | 682.94 Mn |
| Jun 30, 2024 | 792.18 Mn |
| Mar 31, 2024 | 594.49 Mn |
| Dec 31, 2023 | 568.19 Mn |
| Sep 30, 2023 | 773.71 Mn |
| Jun 30, 2023 | 788.41 Mn |
| Mar 31, 2023 | 809.62 Mn |
| Dec 31, 2022 | 803.04 Mn |
| Sep 30, 2022 | 430.96 Mn |
| Jun 30, 2022 | 427.16 Mn |
| Mar 31, 2022 | 443.68 Mn |
| Dec 31, 2021 | 503.61 Mn |
| Sep 30, 2021 | 532.62 Mn |
| Jun 30, 2021 | 254.95 Mn |